After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current momentum—as long as strong clinical data continue to be rewarded and companies ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

The long-awaited Biotech Act will focus on sector financing, clinical trials and incentives for the industry, Euractiv has learned, with the latter already sparking fresh debate. On Tuesday, the ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...

Comprehensively resolving the cell state landscape requires integrating single-cell omics data from diverse studies. We developed CONCORD, a contrastive learning framework that leverages principled ...

Comprehensively resolving the cell state landscape requires integrating single-cell omics data from diverse studies. We developed CONCORD, a contrastive learning framework that leverages principled ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand for 2026's first ...